Featured Research

from universities, journals, and other organizations

Study Of Flu Patients Reveals Virus Outsmarting Key Drug

Date:
September 13, 2004
Source:
University Of Wisconsin-Madison
Summary:
A drug envisioned as a front-line defense for the next flu pandemic might have a genetic Achilles' heel that results in a drug-resistant influenza virus capable of infecting new human hosts, according to a study published this week (Aug. 28) in the British medical journal The Lancet.

MADISON - A drug envisioned as a front-line defense for the next flu pandemic might have a genetic Achilles' heel that results in a drug-resistant influenza virus capable of infecting new human hosts, according to a study published this week (Aug. 28) in the British medical journal The Lancet.

The study of Japanese children with influenza and treated with the antiviral drug oseltamivir was conducted by an international team of researchers led by virologist Yoshihiro Kawaoka of the University of Wisconsin-Madison and the University of Tokyo. Results of the study showed that nearly 20 percent of patients treated with the drug produced mutant drug-resistant viruses as soon as four days after treatment. Moreover, patients continued to shed significant amounts of infectious viral particles even after five days of treatment with the potent antiviral agent.

"The problem with this compound is that a single (genetic) mutation makes the virus resistant," says Kawaoka, an authority on influenza who holds an appointment at the UW-Madison School of Veterinary Medicine.

The finding is important because it provides evidence that influenza viruses can easily and quickly thwart one of the few lines of defense for a disease that claims many lives each year and that, in a pandemic, is among the world's most feared and deadly diseases.

"The importance of this work is that when a pandemic occurs with a new virus and this drug is extensively used, then we may be faced with the rapid appearance of resistant viruses," Kawaoka says.

At present, there are only two strategies for stemming the spread of influenza: vaccines and antiviral drugs. Vaccines use inactivated forms of a virus to ramp up the immune system and thwart infection. Antiviral drugs such as oseltamivir work by inhibiting key proteins on the surface of the virus, effectively locking them in their host cells and preventing the virus from escaping and infecting new cells and hosts.

In a pandemic caused by a new strain of flu virus, new vaccines would need to be developed to cope with changes the virus creates to escape immune detection in host animals. But vaccines take six months or longer to develop and produce in quantity. In the event of an influenza pandemic, when a virulent new form of the flu virus emerges and poses a global health threat, antiviral drugs are viewed as a stopgap, a way to buy time while new vaccines are developed and rushed into production.

The last flu pandemic was in 1968. The influenza pandemic of 1918 was a global tragedy, claiming 21 million lives - more than died in battle in World War I. One billion people - nearly half of the earth's population at the time - were infected.

The new study of Japanese children portrays what might happen in a pandemic as the immune system of a child, never before exposed to a flu virus, mirrors the adult human immune system exposed to the new, more virulent forms of flu virus at the root of pandemics.

"Most of the children we looked at are younger than 3 years old," Kawaoka explains. "They're encountering the flu virus for the first time. In this respect, our population of patients might be considered comparable to one experiencing pandemic influenza in the absence of pre-existing immunity."

The study of 50 Japanese children with influenza, says Kawaoka, suggests that oseltamivir-resistant viruses arise frequently in children treated with the drug.

"We don't know how virulent these viruses are, but they can be a source of another infection, possibly by resistant viruses," he says.

Oseltamivir is a well-known drug and is widely used in Japan. Its use in the United States is restricted, primarily because of cost.

Kawaoka emphasized that while the emergence of resistant flu virus was worrisome, the compound oseltamivir is still a valuable therapeutic drug.

"This is still a good compound," he says. "As with any antiviral compound, the therapeutic value of these agents can be compromised by the emergence of drug-resistant mutants."

In addition to Kawaoka, co-authors of The Lancet paper include Maki Kiso, Keiko Mitamura, Yuko Sakai-Tagawa, Kyoko Shiraishi, Chiharu Kawakami, Kazuhiro Kimura, Frederick G. Hayden and Norio Sugaya.

The research was support by the U.S. National Institutes of Health, the Japan Science and Technology Corp., the Japanese Ministry of Education, Culture, Sports, Science and Technology, and the Japanese Ministry of Health.


Story Source:

The above story is based on materials provided by University Of Wisconsin-Madison. Note: Materials may be edited for content and length.


Cite This Page:

University Of Wisconsin-Madison. "Study Of Flu Patients Reveals Virus Outsmarting Key Drug." ScienceDaily. ScienceDaily, 13 September 2004. <www.sciencedaily.com/releases/2004/09/040913085914.htm>.
University Of Wisconsin-Madison. (2004, September 13). Study Of Flu Patients Reveals Virus Outsmarting Key Drug. ScienceDaily. Retrieved August 21, 2014 from www.sciencedaily.com/releases/2004/09/040913085914.htm
University Of Wisconsin-Madison. "Study Of Flu Patients Reveals Virus Outsmarting Key Drug." ScienceDaily. www.sciencedaily.com/releases/2004/09/040913085914.htm (accessed August 21, 2014).

Share This




More Health & Medicine News

Thursday, August 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
Ramen Health Risks: The Dark Side of the Noodle

Ramen Health Risks: The Dark Side of the Noodle

AP (Aug. 21, 2014) South Koreans eat more instant ramen noodles per capita than anywhere else in the world. But American researchers say eating too much may increase the risk of diabetes, heart disease and stroke. (Aug. 21) Video provided by AP
Powered by NewsLook.com
Possible Ebola Patient in Isolation at California Hospital

Possible Ebola Patient in Isolation at California Hospital

Reuters - US Online Video (Aug. 20, 2014) A patient who may have been exposed to the Ebola virus is in isolation at the Kaiser Permanente South Sacramento Medical Center. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins